Alliance for Clinical Trials in Oncology
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 251
- Market Cap
- -
Breast Cancer WEight Loss Study (BWEL Study)
- Conditions
- Breast Carcinoma
- Interventions
- Other: Health Education ProgramOther: Weight Loss Intervention
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 3177
- Registration Number
- NCT02750826
- Locations
- 🇺🇸
Southern Cancer Center PC-Daphne, Daphne, Alabama, United States
🇺🇸Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
🇺🇸Katmai Oncology Group, Anchorage, Alaska, United States
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 46
- Registration Number
- NCT02749903
- Locations
- 🇺🇸
Greenville Health System Cancer Institute-Easley, Easley, South Carolina, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Dayton Physicians LLC-Wayne, Greenville, Ohio, United States
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- Conditions
- Intracranial MeningiomaRecurrent MeningiomaNF2 Gene Mutation
- Interventions
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 124
- Registration Number
- NCT02523014
- Locations
- 🇺🇸
Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Arizona Oncology Services Foundation, Scottsdale, Arizona, United States
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
- Conditions
- Solitary Osseous Plasmacytoma
- Interventions
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 11
- Registration Number
- NCT02516423
- Locations
- 🇺🇸
Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States
🇺🇸Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸Illinois CancerCare-Galesburg, Galesburg, Illinois, United States
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
- Conditions
- Brain MetastasesRadionecrosis
- Interventions
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 19
- Registration Number
- NCT02490878
- Locations
- 🇺🇸
Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
🇺🇸Memorial Health University Medical Center, Savannah, Georgia, United States
🇺🇸Summit Cancer Care-Memorial, Savannah, Georgia, United States
FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer
- Conditions
- Adenocarcinoma of the Gastroesophageal JunctionGastric AdenocarcinomaGastric Cancer
- Interventions
- Procedure: surgeryProcedure: FDG-PETRadiation: 3D-CRTRadiation: IMRT
- First Posted Date
- 2015-06-30
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 5
- Registration Number
- NCT02485834
- Locations
- 🇺🇸
Regional Hematology and Oncology PA, Newark, Delaware, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Englewood Hospital and Medical Center, Englewood, New Jersey, United States
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
- Conditions
- Germ Cell TumorTeratomaChoriocarcinomaGerminomaMixed Germ Cell TumorYolk Sac TumorChildhood TeratomaMalignant Germ Cell NeoplasmExtragonadal SeminomaNon-seminomatous Germ Cell Tumor
- Interventions
- Drug: pegylated G-CSFProcedure: stem cell reinfusion
- First Posted Date
- 2015-03-02
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 420
- Registration Number
- NCT02375204
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
- Conditions
- Small Cell Lung CancerExtrahepatic Bile Duct CancerMalignant MesotheliomaNon-small Cell Lung CancerDepressionAnxiety DisorderGastric CancerLiver CancerPancreatic CancerEsophageal Cancer
- Interventions
- Other: Early palliative care
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 405
- Registration Number
- NCT02349412
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Queen's Medical Center, Honolulu, Hawaii, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
- Conditions
- Chemotherapeutic Agent ToxicityNeuropathyNeurotoxicity SyndromePainStage IIIA Fallopian Tube CancerStage IIIA Ovarian CancerStage IIIA Primary Peritoneal CancerStage IIIB Fallopian Tube CancerStage IIIB Primary Peritoneal CancerStage IIIB Ovarian Cancer
- Interventions
- Other: Laboratory Biomarker AnalysisOther: PlaceboOther: Quality-of-Life Assessment
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 195
- Registration Number
- NCT02311907
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States
🇺🇸Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 15
- Registration Number
- NCT02249949
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Rush - Copley Medical Center, Aurora, Illinois, United States
🇺🇸Illinois CancerCare-Canton, Canton, Illinois, United States